Insider Purchases: Inside the Buy
Tag: FUNstock Index
Insider Buys Corpay: Should You?
Corpay doesn’t scream for attention — it processes payments quietly, profitably, and at massive scale. With its first-ever insider buy, overwhelming institutional ownership, and a pivot toward higher-growth B2B payments, CPAY might be one of the market’s most overlooked compounders.
Insider Buys AAON’s Cool Air and Open Windows: Should You Be a Fan?
AAON is cooling data centers — and heating up investor debate. With insider buying, record backlog, and AI-driven demand tailwinds, the business looks strong. The stock? Still pricey. Let’s break it down — helmet on. ❄️🪖
Navan Insiders Say En Avant! — But Financials Say NAVN Buyers Should Navigate Carefully
Navan insiders are buying big and analysts see 50%+ upside — but beneath the AI-powered travel platform lies a complex mix of GAAP losses, cash-flow noise, and execution risk. Here’s how to navigate NAVN wisely.
Apple CEO & Nike Director Tim Cook Buys Shares: Is NKE Ready to Sprint?
Nike is down nearly 70% from its peak — but insiders are stepping in. When Apple CEO and Nike director Tim Cook buys nearly $3 million worth of shares, it raises an interesting question: is the swoosh warming up for a comeback sprint?
AirJoule Technologies (AIRJ): Water From Thin Air — and a Stock With Serious Upside?
AirJoule is building technology to extract pure water from air using waste heat — targeting data centers, industry, and defense. The vision is compelling, the partnerships are real, and the risks are just as real. This is a venture-style bet, not a safe harbor.
Ex-Morgan Stanley CEO Gorman Buys Disney: Time For Wonderland — or Better Questions?
Ex-Morgan Stanley CEO James Gorman just bought Disney stock — and institutions are quietly increasing exposure. Shorts are gone, cash flow is up, buybacks are back. Is the magic really returning? 🎬✨
Director Purchases Shares of Johnson & Johnson
A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?